2-[(2-Acetyloxy-3-hexadecoxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium | 77286-68-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 2-[(2-Acetyloxy-3-hexadecoxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
• CAS: 77286-68-1
• 化学式: C26H55NO7P+
• 分子量: 524.7
• InChiKey: HVAUUPRFYPCOCA-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  35
• 可旋转键数：
  26
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  91.3
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• WGK Germany：
  3
• 海关编码：
  2923900090

文献信息

• ANTI-PAF ANTIBODIES
  申请人：SABBADINI Roger A.

  公开号：US20110212088A1

  公开（公告）日：2011-09-01

  Monoclonal antibodies to platelet activating factor (PAF) are described, along with methods for their production and use. Such antibodies can be formulated and used for therapeutic purposes, as well as for diagnosis and detection.

  本文描述了单克隆抗体对血小板活化因子（PAF）的制备和使用方法。这种抗体可以制备并用于治疗目的，以及用于诊断和检测。
• Means and Methods for the Treatment and Prevention of Allergic Diseases
  申请人：Braxmeier Tobias

  公开号：US20090018105A1

  公开（公告）日：2009-01-15

  The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization. Preferred in this context are edelfosine and miltefosine. In a particularly preferred embodiment, the present invention relates to the use of miltefosine for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of allergic diseases, in particular acute hyperallergic diseases, like asthma.
• Humanized platelet activating factor antibody design using anti-lipid antibody templates
  申请人：SABBADINI ROGER A.

  公开号：US20100292443A1

  公开（公告）日：2010-11-18

  Methods for designing a humanized antibody to platelet activating factor are provided. These methods may be performed in silico.
• METHODS FOR THE TREATMENT AND AMELIORATION OF ATOPIC DERMATITIS
  申请人：BRAXMEIER Tobias

  公开号：US20110263531A1

  公开（公告）日：2011-10-27

  The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization and/or activation. Preferred in this context are Edelfosine, Miltefosine and Perifosine. In a particularly preferred embodiment, the present invention relates to the use of Miltefosine for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of allergic diseases, in particular acute hyperallergic diseases, like asthma, atopic dermatitis and mastocytosis.
• REGULATED BIOCIRCUIT SYSTEMS
  申请人：Obsidian Therapeutics, Inc.

  公开号：US20190192691A1

  公开（公告）日：2019-06-27

  The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.